Browsing Tag
Johnson & Johnson
119 posts
Oruka Therapeutics stock surges as ORKA-001 psoriasis trial success puts $1.1bn biotech strategy to the test
Oruka Therapeutics stock rallies after ORKA-001 delivers 61% psoriasis clearance. Explore its $1.1B cash position and Phase 3 growth potential.
Genmab targets new oncology growth as Rina-S delivers major survival gains over chemotherapy
Genmab stock jumps 9.5% after Rina-S delivers major ovarian cancer survival gains. Explore its FDA prospects, competition and growth outlook.
Odyssey Therapeutics targets major inflammatory bowel disease opportunity with oral OD-001
Odyssey Therapeutics stock rises on OD-001 ulcerative colitis results. Explore its $433M cash position, clinical trials and growth prospects.
Johnson & Johnson revenue reaches $25.4bn as $5.5bn legal charge weighs on profits
Johnson & Johnson reported 5.9% revenue growth in the third quarter of 2026 and lifted its annual sales outlook, but a major litigation-related charge reduced reported earnings to $210 million while the company's medical technology business continued facing commercial pressure.
ArriVent shares plunge as FURVENT miss shifts attention to PACC lung cancer and ADC pipeline
ArriVent shares plunge after firmonertinib misses the FURVENT Phase 3 endpoint, putting its first-line exon 20 lung cancer strategy at risk.
Legend Biotech adds five-year durability to CARVYKTI’s rapidly growing commercial story
Legend Biotech reports five-year CARVYKTI remissions as sales rise 50%, strengthening the case for earlier use in multiple myeloma.
Johnson & Johnson’s Caplyta delivers rapid Phase III bipolar mania response
The once-daily medicine reduced manic symptoms by significantly more than placebo and doubled the clinical response rate, advancing a potential new indication for a drug acquired with Intra-Cellular Therapies.
Legend Biotech names Ingrid Zhang CEO as CARVYKTI sales surge 50%
Legend Biotech Corporation has appointed former Novartis commercial executive Ingrid Zhang as chief executive after a seven-week leadership search, putting an experienced global medicines operator in charge as CARVYKTI sales accelerate and the cell therapy company tries to build its next growth engine.
Three-year survival hits 83% as Johnson & Johnson expands TECVAYLI into second-line myeloma
TECVAYLI moves into earlier EU myeloma care after cutting progression risk 83.4%, strengthening Johnson & Johnson’s fast-growing oncology franchise.
Johnson & Johnson clears MONARCH QUEST 3 as bronchoscopy software race accelerates
Johnson & Johnson has secured U.S. 510(k) clearance for MONARCH QUEST 3, adding AI-based nodule segmentation, navigation upgrades and wider cone-beam CT compatibility to its robotic bronchoscopy platform.